---
document_datetime: 2025-12-29 14:34:46
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/temozolomide-accord.html
document_name: temozolomide-accord.html
version: success
processing_time: 0.1253067
conversion_datetime: 2025-12-30 01:36:53.081054
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Temozolomide Accord

[RSS](/en/individual-human-medicine.xml/65924)

##### Authorised

This medicine is authorised for use in the European Union

temozolomide Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Temozolomide Hospira](#more-information-on-temozolomide-hospira-1146)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European Public Assessment Report (EPAR) for Temozolomide Accord. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Temozolomide Accord.

Expand section

Collapse section

## What is Temozolomide Accord?

Temozolomide Accord is a cancer medicine that contains the active substance temozolomide. It is available as capsules (5 mg; 20 mg; 100 mg; 140 mg; 180 mg; 250 mg).

Temozolomide Accord is a 'generic medicine'. This means that Temozolomide Accord is similar to a 'reference medicine' already authorised in the European Union (EU) called Temodal.

## What is Temozolomide Accord used for?

Temozolomide Accord is used to treat malignant glioma (brain tumours) in the following groups of patients:

- adults with newly diagnosed glioblastoma multiforme (an aggressive type of brain tumour). Temozolomide Accord is used first with radiotherapy and then on its own;
- adults and children three years of age and over with malignant glioma such as glioblastoma multiforme or anaplastic astrocytoma, when the tumour has returned or got worse after standard treatment. Temozolomide Accord is used on its own in these patients.

The medicine can only be obtained with a prescription.

## How is Temozolomide Accord used?

Treatment with Temozolomide Accord should be prescribed by a doctor with experience in the treatment of brain tumours.

The dose of Temozolomide Accord depends on body surface area (calculated using the patient's height and weight) and ranges from 75 to 200 mg per square metre, once a day. The dose and the number of doses depend on the type of tumour being treated, whether the patient has been treated before, whether Temozolomide Accord is being used alone or with other treatments, and how the patient responds to treatment. Temozolomide Accord should be taken without food. Patients may also need to take medicines to prevent vomiting before taking Temozolomide Accord.

For full details, see the summary of product characteristics (also part of the EPAR).

## How does Temozolomide Accord work?

The active substance in Temozolomide Accord, temozolomide, belongs to a group of cancer medicines called alkylating agents. In the body, temozolomide is converted to another compound called MTIC. MTIC binds to the DNA of cells while they are reproducing, which stops cell division. As a result, the cancer cells cannot divide, slowing down the growth of tumours.

## How has Temozolomide Accord been studied?

Because Temozolomide Accord is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Temodal. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

## What are the benefit and risk of Temozolomide Accord?

Because Temozolomide Accord is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why has Temozolomide Accord been approved?

The CHMP concluded that, in accordance with EU requirements, Temozolomide Accord has been shown to have comparable quality and to be bioequivalent to Temodal. Therefore, the CHMP's view was that, as for Temodal, the benefit outweighs the identified risk. The Committee recommended that Temozolomide Accord be given marketing authorisation.

## Other information about Temozolomide Accord

The European Commission granted a marketing authorisation valid throughout the EU for Temozolomide Accord on 15 March 2010. The name of the medicine was changed to Temozolomide Accord on 27 May 2015.

For more information about treatment with Temozolomide Accord, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Temozolomide Accord: EPAR - Summary for the public

English (EN) (84.19 KB - PDF)

**First published:** 26/03/2010

**Last updated:** 01/07/2015

[View](/en/documents/overview/temozolomide-accord-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-994)

български (BG) (110.99 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

01/07/2015

[View](/bg/documents/overview/temozolomide-accord-epar-summary-public_bg.pdf)

español (ES) (109.09 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

01/07/2015

[View](/es/documents/overview/temozolomide-accord-epar-summary-public_es.pdf)

čeština (CS) (107.68 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

01/07/2015

[View](/cs/documents/overview/temozolomide-accord-epar-summary-public_cs.pdf)

dansk (DA) (106.74 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

01/07/2015

[View](/da/documents/overview/temozolomide-accord-epar-summary-public_da.pdf)

Deutsch (DE) (86.56 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

01/07/2015

[View](/de/documents/overview/temozolomide-accord-epar-summary-public_de.pdf)

eesti keel (ET) (83.62 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

01/07/2015

[View](/et/documents/overview/temozolomide-accord-epar-summary-public_et.pdf)

ελληνικά (EL) (134.89 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

01/07/2015

[View](/el/documents/overview/temozolomide-accord-epar-summary-public_el.pdf)

français (FR) (108.95 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

01/07/2015

[View](/fr/documents/overview/temozolomide-accord-epar-summary-public_fr.pdf)

hrvatski (HR) (98.64 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

01/07/2015

[View](/hr/documents/overview/temozolomide-accord-epar-summary-public_hr.pdf)

italiano (IT) (106.49 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

01/07/2015

[View](/it/documents/overview/temozolomide-accord-epar-summary-public_it.pdf)

latviešu valoda (LV) (105.39 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

01/07/2015

[View](/lv/documents/overview/temozolomide-accord-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (127.09 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

01/07/2015

[View](/lt/documents/overview/temozolomide-accord-epar-summary-public_lt.pdf)

magyar (HU) (103.37 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

01/07/2015

[View](/hu/documents/overview/temozolomide-accord-epar-summary-public_hu.pdf)

Malti (MT) (112.07 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

01/07/2015

[View](/mt/documents/overview/temozolomide-accord-epar-summary-public_mt.pdf)

Nederlands (NL) (108.13 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

01/07/2015

[View](/nl/documents/overview/temozolomide-accord-epar-summary-public_nl.pdf)

polski (PL) (131.45 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

01/07/2015

[View](/pl/documents/overview/temozolomide-accord-epar-summary-public_pl.pdf)

português (PT) (108.76 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

01/07/2015

[View](/pt/documents/overview/temozolomide-accord-epar-summary-public_pt.pdf)

română (RO) (132.03 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

01/07/2015

[View](/ro/documents/overview/temozolomide-accord-epar-summary-public_ro.pdf)

slovenčina (SK) (131.32 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

01/07/2015

[View](/sk/documents/overview/temozolomide-accord-epar-summary-public_sk.pdf)

slovenščina (SL) (121.42 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

01/07/2015

[View](/sl/documents/overview/temozolomide-accord-epar-summary-public_sl.pdf)

Suomi (FI) (123.86 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

01/07/2015

[View](/fi/documents/overview/temozolomide-accord-epar-summary-public_fi.pdf)

svenska (SV) (85.05 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

01/07/2015

[View](/sv/documents/overview/temozolomide-accord-epar-summary-public_sv.pdf)

## Product information

Temozolomide Accord : EPAR - Product Information

English (EN) (470.27 KB - PDF)

**First published:** 26/03/2010

**Last updated:** 02/06/2025

[View](/en/documents/product-information/temozolomide-accord-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-686)

български (BG) (755.79 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

02/06/2025

[View](/bg/documents/product-information/temozolomide-accord-epar-product-information_bg.pdf)

español (ES) (559.38 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

02/06/2025

[View](/es/documents/product-information/temozolomide-accord-epar-product-information_es.pdf)

čeština (CS) (701 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

02/06/2025

[View](/cs/documents/product-information/temozolomide-accord-epar-product-information_cs.pdf)

dansk (DA) (662.58 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

02/06/2025

[View](/da/documents/product-information/temozolomide-accord-epar-product-information_da.pdf)

Deutsch (DE) (615.05 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

02/06/2025

[View](/de/documents/product-information/temozolomide-accord-epar-product-information_de.pdf)

eesti keel (ET) (612.79 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

02/06/2025

[View](/et/documents/product-information/temozolomide-accord-epar-product-information_et.pdf)

ελληνικά (EL) (743.04 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

02/06/2025

[View](/el/documents/product-information/temozolomide-accord-epar-product-information_el.pdf)

français (FR) (640.78 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

02/06/2025

[View](/fr/documents/product-information/temozolomide-accord-epar-product-information_fr.pdf)

hrvatski (HR) (724.2 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

02/06/2025

[View](/hr/documents/product-information/temozolomide-accord-epar-product-information_hr.pdf)

íslenska (IS) (669.67 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

02/06/2025

[View](/is/documents/product-information/temozolomide-accord-epar-product-information_is.pdf)

italiano (IT) (662.92 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

02/06/2025

[View](/it/documents/product-information/temozolomide-accord-epar-product-information_it.pdf)

latviešu valoda (LV) (744.97 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

02/06/2025

[View](/lv/documents/product-information/temozolomide-accord-epar-product-information_lv.pdf)

lietuvių kalba (LT) (668.89 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

02/06/2025

[View](/lt/documents/product-information/temozolomide-accord-epar-product-information_lt.pdf)

magyar (HU) (1.18 MB - PDF)

**First published:**

26/03/2010

**Last updated:**

02/06/2025

[View](/hu/documents/product-information/temozolomide-accord-epar-product-information_hu.pdf)

Malti (MT) (1.11 MB - PDF)

**First published:**

26/03/2010

**Last updated:**

02/06/2025

[View](/mt/documents/product-information/temozolomide-accord-epar-product-information_mt.pdf)

Nederlands (NL) (622.7 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

02/06/2025

[View](/nl/documents/product-information/temozolomide-accord-epar-product-information_nl.pdf)

norsk (NO) (703.34 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

02/06/2025

[View](/no/documents/product-information/temozolomide-accord-epar-product-information_no.pdf)

polski (PL) (670.75 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

02/06/2025

[View](/pl/documents/product-information/temozolomide-accord-epar-product-information_pl.pdf)

português (PT) (630.22 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

02/06/2025

[View](/pt/documents/product-information/temozolomide-accord-epar-product-information_pt.pdf)

română (RO) (755.4 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

02/06/2025

[View](/ro/documents/product-information/temozolomide-accord-epar-product-information_ro.pdf)

slovenčina (SK) (717.15 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

02/06/2025

[View](/sk/documents/product-information/temozolomide-accord-epar-product-information_sk.pdf)

slovenščina (SL) (631.58 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

02/06/2025

[View](/sl/documents/product-information/temozolomide-accord-epar-product-information_sl.pdf)

Suomi (FI) (649.65 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

02/06/2025

[View](/fi/documents/product-information/temozolomide-accord-epar-product-information_fi.pdf)

svenska (SV) (683.61 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

02/06/2025

[View](/sv/documents/product-information/temozolomide-accord-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000272235 28/05/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Temozolomide Accord : EPAR - All Authorised presentations

English (EN) (17.32 KB - PDF)

**First published:** 26/03/2010

**Last updated:** 08/07/2015

[View](/en/documents/all-authorised-presentations/temozolomide-accord-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-216)

български (BG) (41.47 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

08/07/2015

[View](/bg/documents/all-authorised-presentations/temozolomide-accord-epar-all-authorised-presentations_bg.pdf)

español (ES) (17.91 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

08/07/2015

[View](/es/documents/all-authorised-presentations/temozolomide-accord-epar-all-authorised-presentations_es.pdf)

čeština (CS) (38.73 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

08/07/2015

[View](/cs/documents/all-authorised-presentations/temozolomide-accord-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (17.77 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

08/07/2015

[View](/da/documents/all-authorised-presentations/temozolomide-accord-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (46.24 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

08/07/2015

[View](/de/documents/all-authorised-presentations/temozolomide-accord-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (17.97 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

08/07/2015

[View](/et/documents/all-authorised-presentations/temozolomide-accord-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (42.89 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

08/07/2015

[View](/el/documents/all-authorised-presentations/temozolomide-accord-epar-all-authorised-presentations_el.pdf)

français (FR) (17.72 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

08/07/2015

[View](/fr/documents/all-authorised-presentations/temozolomide-accord-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (37.15 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

08/07/2015

[View](/hr/documents/all-authorised-presentations/temozolomide-accord-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (17.81 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

08/07/2015

[View](/is/documents/all-authorised-presentations/temozolomide-accord-epar-all-authorised-presentations_is.pdf)

italiano (IT) (17.47 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

08/07/2015

[View](/it/documents/all-authorised-presentations/temozolomide-accord-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (38.1 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

08/07/2015

[View](/lv/documents/all-authorised-presentations/temozolomide-accord-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (38.17 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

08/07/2015

[View](/lt/documents/all-authorised-presentations/temozolomide-accord-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (39.77 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

08/07/2015

[View](/hu/documents/all-authorised-presentations/temozolomide-accord-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (37.86 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

08/07/2015

[View](/mt/documents/all-authorised-presentations/temozolomide-accord-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (17.58 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

08/07/2015

[View](/nl/documents/all-authorised-presentations/temozolomide-accord-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (17.89 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

08/07/2015

[View](/no/documents/all-authorised-presentations/temozolomide-accord-epar-all-authorised-presentations_no.pdf)

polski (PL) (38.02 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

08/07/2015

[View](/pl/documents/all-authorised-presentations/temozolomide-accord-epar-all-authorised-presentations_pl.pdf)

português (PT) (18.47 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

08/07/2015

[View](/pt/documents/all-authorised-presentations/temozolomide-accord-epar-all-authorised-presentations_pt.pdf)

română (RO) (37.34 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

08/07/2015

[View](/ro/documents/all-authorised-presentations/temozolomide-accord-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (37.66 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

08/07/2015

[View](/sk/documents/all-authorised-presentations/temozolomide-accord-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (32.29 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

08/07/2015

[View](/sl/documents/all-authorised-presentations/temozolomide-accord-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (17.87 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

08/07/2015

[View](/fi/documents/all-authorised-presentations/temozolomide-accord-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (17.7 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

08/07/2015

[View](/sv/documents/all-authorised-presentations/temozolomide-accord-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Temozolomide Accord Active substance temozolomide International non-proprietary name (INN) or common name temozolomide Therapeutic area (MeSH) Glioma Anatomical therapeutic chemical (ATC) code L01AX03

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

For the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment.

For the treatment of children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.

## Authorisation details

EMA product number EMEA/H/C/001125

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Accord Healthcare S.L.U.

Edificio Este Planta 6a

Opinion adopted 17/12/2009 Marketing authorisation issued 15/03/2010 Revision 25

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Temozolomide Accord : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (125.8 KB - PDF)

**First published:** 02/06/2025

[View](/en/documents/procedural-steps-after/temozolomide-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Temozolomide Accord : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (186.02 KB - PDF)

**First published:** 08/07/2011

**Last updated:** 02/06/2025

[View](/en/documents/procedural-steps-after/temozolomide-accord-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Temozolomide Hospira : EPAR - Public assessment report

English (EN) (310.93 KB - PDF)

**First published:** 26/03/2010

**Last updated:** 26/03/2010

[View](/en/documents/assessment-report/temozolomide-hospira-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Temozolomide Hospira

Adopted

Reference Number: EMA/CHMP/810712/2009

English (EN) (32.14 KB - PDF)

**First published:** 17/12/2009

**Last updated:** 17/12/2009

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-temozolomide-hospira_en.pdf)

#### More information on Temozolomide Hospira

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-573)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 02/06/2025

## Share this page

[Back to top](#main-content)